Cytokinetics, Inc. (CYTK)
61.23
-1.10
(-1.76%)
USD |
NASDAQ |
Oct 23, 16:00
61.23
0.00 (0.00%)
After-Hours: 20:00
Cytokinetics Enterprise Value : 8.598B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 8.598B |
| October 22, 2026 | 8.751B |
| October 21, 2026 | 8.824B |
| October 20, 2026 | 8.976B |
| October 19, 2026 | 8.795B |
| October 16, 2026 | 8.698B |
| October 15, 2026 | 8.971B |
| October 14, 2026 | 8.903B |
| October 13, 2026 | 8.652B |
| October 12, 2026 | 8.815B |
| October 09, 2026 | 8.831B |
| October 08, 2026 | 8.706B |
| October 07, 2026 | 8.583B |
| October 06, 2026 | 8.615B |
| October 05, 2026 | 8.802B |
| October 02, 2026 | 9.205B |
| October 01, 2026 | 9.207B |
| September 30, 2026 | 9.248B |
| September 29, 2026 | 9.210B |
| September 28, 2026 | 9.282B |
| September 25, 2026 | 9.074B |
| September 24, 2026 | 9.213B |
| September 23, 2026 | 9.234B |
| September 22, 2026 | 9.481B |
| September 21, 2026 | 9.477B |
| Date | Value |
|---|---|
| September 18, 2026 | 9.646B |
| September 17, 2026 | 9.804B |
| September 16, 2026 | 9.730B |
| September 15, 2026 | 9.719B |
| September 14, 2026 | 10.16B |
| September 11, 2026 | 10.34B |
| September 10, 2026 | 10.32B |
| September 09, 2026 | 10.39B |
| September 08, 2026 | 10.56B |
| September 04, 2026 | 10.19B |
| September 03, 2026 | 10.36B |
| September 02, 2026 | 10.08B |
| September 01, 2026 | 10.01B |
| August 31, 2026 | 9.941B |
| August 28, 2026 | 10.11B |
| August 27, 2026 | 10.91B |
| August 26, 2026 | 11.09B |
| August 25, 2026 | 10.85B |
| August 24, 2026 | 10.80B |
| August 21, 2026 | 10.76B |
| August 20, 2026 | 10.81B |
| August 19, 2026 | 10.89B |
| August 18, 2026 | 10.66B |
| August 17, 2026 | 10.63B |
| August 14, 2026 | 10.39B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 159.59B |
| BridgeBio Pharma, Inc. | 16.08B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| BioMarin Pharmaceutical, Inc. | 14.17B |
| Exelixis, Inc. | 15.39B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -198.76M |
| Revenue (Quarterly) | 28.62M |
| Total Expenses (Quarterly) | 227.39M |
| EPS Diluted (Quarterly) | -1.505 |
| Gross Profit Margin (Quarterly) | 67.78% |
| Profit Margin (Quarterly) | -694.4% |
| Earnings Yield | -11.80% |
| Normalized Earnings Yield | -10.76 |